A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
NCT00001209
Completed
This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival in patients with Ewing's sarcoma, primitive sarcoma of bone, peripheral neuroepithelioma, and soft tissue sarcoma. This will not be a randomized study but will be comparable to the large data base of... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma, Sarcoma, Ewing's
Register for Updates
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
NCT00001384
Completed
This is a pilot feasibility trial of AC (Adriamycin, cyclophosphamide) chemotherapy with G-CSF (filgrastim) followed by infusional Taxol (paclitaxel) as adjuvant treatment for patients with high risk stage II and stage III breast cancer. Cycles will be 14 days in duration. After 3 fourteen day cycles of AC with filgrastim, patients will be treated with 3 fourteen day cycles of 96 hour infusional paclitaxel. The goal of this study will be to assess the toxicity and feasibility of administering do... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
NCT00001498
Completed
Stage III patients may begin therapy prior to or following surgery. Patients with undrainable significant third space fluid collection (e.g., pleural effusions, ascites) are entered directly on Consolidation. Patients receive induction chemotherapy with methotrexate and fluorouracil every 2 weeks for 4 courses. Patients then receive two 3-week courses of consolidation therapy with cyclophosphamide, followed by daily granulocyte colony-stimulating factor until completion of leukapheresis. Patie... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Treatment of Wegener's Granulomatosis With Cyclophosphamide
NCT00001155
Completed
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland
Conditions: Vasculitis, Wegener's Granulomatosis
Register for Updates
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
NCT00040651
Terminated
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs. The purpose of this study is to determine the safety and value of self bone marrow transplants after chemotherapy in patients with severe SSc.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/19/2007
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Scleroderma, Systemic Sclerosis
Register for Updates
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
NCT00333008
Unknown
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2006
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland +1 locations
Conditions: Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Register for Updates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT00131313
Unknown
This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2005
Locations: Northwest Alabama Cancer Center, PC, Muscle Shoals, Alabama +51 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
NCT00006055
Unknown
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II. Determine the kinetics of T- and B-cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and posttransplant immunosuppression with cyclosporine in these patients. III. Determine whether this treatment re... Read More
Gender:
ALL
Ages:
Between 1 year and 55 years
Trial Updated:
06/23/2005
Locations: Fairview University Medical Center, Minneapolis, Minnesota
Conditions: Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Register for Updates
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
NCT00006056
Unknown
OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders. II. Determine the rate of disease free survival, incidence of graft failure, and incidence of graft versus host disease in these patients after undergoing this treatment regimen.
Gender:
ALL
Ages:
Between 0 years and 55 years
Trial Updated:
06/23/2005
Locations: Fairview University Medical Center, Minneapolis, Minnesota
Conditions: Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Virus-Associated Hemophagocytic Syndrome
Register for Updates
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
NCT00014755
Completed
OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple sclerosis. II. Determine the disease response of patients treated with this regimen. III. Determine the safety and efficacy of filgrastim (G-CSF) for PBSC mobilization in this patient population.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/23/2005
Locations: City of Hope National Medical Center, Duarte, California +5 locations
Conditions: Multiple Sclerosis
Register for Updates
Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
NCT00017628
Completed
OBJECTIVES: I. Determine the efficacy, in terms of disease progression, of high-dose cyclophosphamide and total body irradiation with T lymphocyte-depleted autologous peripheral blood stem cell or bone marrow rescue in patients with multiple sclerosis.
Gender:
ALL
Ages:
Between 0 years and 59 years
Trial Updated:
06/23/2005
Locations: Northwestern Memorial Hospital, Chicago, Illinois +1 locations
Conditions: Multiple Sclerosis
Register for Updates
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
NCT00010400
Completed
OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/23/2005
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland +1 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
Register for Updates